#USA #New York #Levi & Korsinsky #Rocket Pharmaceuticals #RCKT

Join the Class Action Against Rocket Pharmaceuticals

Levi & Korsinsky, LLP is reaching out to investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), inviting them to participate in a class action lawsuit. This action stems from allegations of securities fraud that could significantly affect shareholders.

Class Definition

The proposed class action aims to recover losses sustained by investors during the period of September 17, 2024, to May 26, 2025. This time frame captured the alleged misconduct that misled investors and inflated stock prices beyond their actual value.

Understanding the Allegations

According to the complaint filed, the defendants provided overly optimistic projections to investors, while concealing critical information about RP-A501's safety and the clinical trial protocol. Specifically, the lawsuit points out that Rocket Pharmaceuticals was aware of Serious Adverse Events (SAEs), including patient fatalities, associated with the trials but failed to disclose these risks adequately.

In a pivotal move, the company modified the clinical trial protocol to incorporate a new immunomodulatory agent into the treatment regimen. This critical change was not communicated to shareholders, creating an information gap that led investors to secure Rocket's stocks at artificially elevated prices.

On May 27, 2025, the financial landscape shifted dramatically when Rocket announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 trial after one patient experienced an SAE that resulted in death. Following this revelation, Rocket's stock plummeted from a closing price of $6.27 on May 23, 2025, to $2.33 just days later, marking a staggering decline of around 37% in a single trading day.

What Investors Should Know

Investors who experienced losses during the stated timeline have until August 11, 2025, to petition the Court for appointment as lead plaintiff. It's important to clarify that one does not need to serve as lead plaintiff to qualify for potential recovery in this case.

No Costs Involved

For those classified as class members, there's no obligation or initial fee to participate in this lawsuit. There are no costs or hidden fees related to pursuing potential compensation. The firm will handle all legal expenses, ensuring that financial barriers do not recline eligible investors from seeking redress.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has acquired substantial experience in representing investors in securities-related litigation over the past two decades. The firm has managed to recover hundreds of millions of dollars for investors who have encountered fraud or misrepresentation. Their team, consisting of more than 70 skilled professionals, is well-versed in complex legalities and prepares each case rigorously to maximize their clients' chances of a favorable outcome.

Furthermore, the firm has consistently ranked among the top securities litigation companies, demonstrating ongoing commitment and success in advocating for shareholder rights.

How to Get Involved

To learn more about the lawsuit or to initiate the process to join, investors are encouraged to fill out a submission form available through their website. Those interested can also contact Joseph E. Levi, Esq. via email at [email protected] or by calling (212) 363-7500 directly.

As the deadline approaches, Rocket Pharmaceuticals investors should act quickly to ensure their voices are heard through this class action. Don't miss this opportunity for justice and potential restitution.